Acorda Provides Financial and Pipeline Update for First Quarter 2017
Acorda Therapeutics, Inc. (ACOR)
Last acorda therapeutics, inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acorda.com/investors
Company Research
Source: Business Wire
Corporate restructuring implemented to focus on late-stage Parkinson’s programs 2017 combined R&D and SG&A operating expense guidance revised to $330 - $350 million, a reduction of ~$50 million Projected year-end cash balance greater than $200 million AMPYRA® (dalfampridine) 1Q 2017 net revenue of $112.0 million; Company reiterates AMPYRA net sales guidance of $535 - $545 million ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced financial results for its first quarter ended March 31, 2017, and provided an update on the Company’s pipeline, financial guidance and corporate restructuring. As previously announced, following the decision by the United States District Court for the District of Delaware invalidating certain patents pertaining to AMPYRA®, Acorda implemented a corporate restruc
Show less
Read more
Impact Snapshot
Event Time:
ACOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACOR alerts
High impacting Acorda Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACOR
News
- Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
- Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024Business Wire
- Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
- Klick Health Launches First AI Social Media Comment Moderator for Life Sciences Industry [Yahoo! Finance]Yahoo! Finance
- Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
ACOR
Sec Filings
- 3/13/24 - Form 8-K
- 1/11/24 - Form 8-K
- ACOR's page on the SEC website